| Zhu Yaoyao,Yang Shuangyan,Yang Wenyan,Lin Qingren,Shao Kainan,Xu Qinghua,Liu hui,Xu Yaping.Clinical outcomes of stereotactic body radiation therapy for T2N0M0 non-small cell lung cancer[J].Chinese Journal of Radiological Medicine and Protection,2019,39(12):904-909 |
| Clinical outcomes of stereotactic body radiation therapy for T2N0M0 non-small cell lung cancer |
| Received:July 24, 2019 |
| DOI：10.3760/cma.j.issn.0254-5098.2019.12.005 |
| KeyWords:Stereotactic body radiation therapy Non-small cell lung cancer Overall survival Progression-free survival Cause-specific survival |
| FundProject:山东省重点研发计划项目（2018GSF118048） |
| Author Name | Affiliation | E-mail | | Zhu Yaoyao | First Clinical Medical School, Wenzhou Medical University, Wenzhou 325035, China | | | Yang Shuangyan | Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China | | | Yang Wenyan | Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China | | | Lin Qingren | Department of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences, Hangzhou 310022, China | | | Shao Kainan | Department of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences, Hangzhou 310022, China | | | Xu Qinghua | Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China | | | Liu hui | Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China | | | Xu Yaping | First Clinical Medical School, Wenzhou Medical University, Wenzhou 325035, China | xuyaping1207@163.com |
|
| Hits: 1830 |
| Download times: 1190 |
| Abstract:: |
| Objective To investigate the clinical efficacy and adverse effects of stereotactic body radiotherapy (SBRT) in the treatment of T2N0M0 non-small cell lung cancer (NSCLC) patients. Methods By retrospectively analyzing the clinical data of 30 inoperable patients with stage T2N0M0 NSCLC treated by SBRT, the overall survival, progression-free survival, cancer-specific survival and adverse effects were determined. Results The median follow-up was 18.4 months. The 1-, 2-, and 3-year overall survival rates were 92.2%, 92.2% and 80.6%, respectively. The corresponding cause-specific survivals were 95.7%, 95.7% and 83.7%. The progression-free survivals were 70.2%, 54.1% and 40.6%. The local control rates were 100%, 94.4%, and 94.4%. The regional controls were 84.2%, 72.1%, and 54.1%; and distant controls were 84.6%, 72.4% and 64.3%, respectively. Twenty patients (66.7%) developed symptoms of grade 1 radiation-related toxicities:dyspnea, chest pain, fatigue, cough, esophagitis, or pneumonia. Among these, 5 patients suffered grade ≥ 2 radiation pneumonitis, and one patient experienced grade 4 radiation pneumonitis. Conclusions SBRT was efficient and safe for patients with inoperable T2N0M0 NSCLC, imposing tolerable toxicities. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
